MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 535186 | Name: Cedirogant
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cedirogant is a retinoid-related orphan receptor-γt (RORγt) antagonist.

Chemical Structure

Cedirogant
Cedirogant
CAS#2055496-11-0

Theoretical Analysis

MedKoo Cat#: 535186

Name: Cedirogant

CAS#: 2055496-11-0

Chemical Formula: C24H20Cl3F3N2O3

Exact Mass: 546.0492

Molecular Weight: 547.78

Elemental Analysis: C, 52.62; H, 3.68; Cl, 19.41; F, 10.40; N, 5.11; O, 8.76

Price and Availability

Size Price Availability Quantity
10mg USD 250.00 2 Weeks
25mg USD 450.00 2 Weeks
50mg USD 750.00 2 Weeks
100mg USD 1,250.00 2 Weeks
200mg USD 1,950.00 2 Weeks
500mg USD 3,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Cedirogant; ABBV-157; ABBV 157; ABBV157; WHO 11460; WHO-11460; WHO11460;
IUPAC/Chemical Name
[1-(2,4-dichloro-3-{[7-chloro-5-(trifluoromethyl)-1Hindol-1-yl]methyl}benzoyl)piperidin-4-yl]acetic acid
InChi Key
MNEOHCYSHVKLIC-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H20Cl3F3N2O3/c25-18-2-1-16(23(35)31-6-3-13(4-7-31)9-20(33)34)21(27)17(18)12-32-8-5-14-10-15(24(28,29)30)11-19(26)22(14)32/h1-2,5,8,10-11,13H,3-4,6-7,9,12H2,(H,33,34)
SMILES Code
O=C(O)CC1CCN(C(C2=CC=C(Cl)C(CN3C=CC4=C3C(Cl)=CC(C(F)(F)F)=C4)=C2Cl)=O)CC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 547.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tyring S, Moore A, Morita A, Hong HC, Song IH, Eccleston J, Levy G, Mohamed MF, Qian Y, Wu T, Pan A, Hew K, Papp KA. Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial. Clin Exp Dermatol. 2024 Oct 24;49(11):1347-1355. doi: 10.1093/ced/llae152. PMID: 38699939. 2: Kikuchi R, Qian Y, Badawi M, Savaryn JP, Gannu S, Eldred A, Hao S, Salem AH, Liu W, Klein CE, Mohamed MF. Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case Study. Clin Pharmacol Ther. 2024 Nov;116(5):1334-1342. doi: 10.1002/cpt.3399. Epub 2024 Aug 5. PMID: 39102854. 3: Mohamed MF, Qian Y, D'Cunha R, Sligh T, Ferris LK, Eldred A, Levy GF, Hao S, Gannu S, Rizzo DG, Liu W, Jazayeri S, Sofen H, Carcereri De Prati R. Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Clin Transl Sci. 2024 Jan;17(1):e13682. doi: 10.1111/cts.13682. Epub 2023 Dec 19. PMID: 38112262; PMCID: PMC10766045. 4: Maier CS, Eckert D, Laroux FS, Hew KM, Suleiman AA, Liu W, Mohamed MF. Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis. Clin Pharmacol Drug Dev. 2024 May;13(5):474-484. doi: 10.1002/cpdd.1377. Epub 2024 Jan 17. PMID: 38231873. 5: Mohamed MF, Qian Y, D'Cunha R, Hao S, Carcereri De Prati R, Levy GF, Hew K, Liu W. Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults. Clin Pharmacol Drug Dev. 2024 Jul;13(7):801-809. doi: 10.1002/cpdd.1386. Epub 2024 Feb 27. PMID: 38410874. 6: Gege C. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases - where are we presently? Expert Opin Drug Discov. 2021 Dec;16(12):1517-1535. doi: 10.1080/17460441.2021.1948833. Epub 2021 Jul 7. PMID: 34192992.

View History

CDPPB

CDPPB

New Featured